^(131)I-VIP的制备及VIP受体显像  

Preparation of ^(131)IVIP and ^(131)IVIP ReceptorImaging

作　　者：史育红[1] 谭天秩[1] 

机构地区：[1]华西医科大学附属第一医院核医学科,成都610041

出　　处：《华西医科大学学报》2000年第3期292-294,共3页Journal of West China University of Medical Sciences

基　　金：国家自然科学基金!(批准号39570225)

摘　　要：为制备高比放、高放化纯的131I－血管活性肠肽(VIP)并初步探讨其临床应用价值。采用CH－T法用131I标记VIP，并用Sephadex G－10柱层析分离纯化，硅胶60F254薄板层析（TLC）检测。131I－VIP使用前进行灭菌处理,同时进行细菌、热源及安全性鉴定。注射131I－VIP后0.5小时、2～4小时、18～24小时用单探头SPECT采集颈部、胸部及腹部平面图像。结果显示：细菌培养、热源鉴定及安全性结果为阴性，符合体内用药要求；碘标记率80%，比放射性36TBq/mmol。注入的131I－VIP迅速由血循环中清除，主要浓集于肺。2小时后胃部出现明显的放射性核素分布，并随时间延长而增浓。肿瘤灶在注射131I－VIP后0.5～3小时显影，24小时后仍清晰可见。以上表明：Sephadex G－10柱层析法分离纯化131I－VIP 标记混合物简便、快速、有效。131I－VIP受体显像可显示VIP受体阳性肿瘤，但131I－VIP体内脱碘造成胃区放射性核素浓集是其主要缺点，尚有待于深入研究克服。This study was aimed at the preparation of 131I－vasoact ive intestinal peptide (VIP) and its preliminary application in clinical imaging .VIP was labeled with Na 131I using chlora mine－T method, then isolated by Sephadex G－10 column chromatography and examined by silica 60F254 thinlayer chromatography. The bacteria and pyrogen were examined and the safety test was carried out. One control and two patients suffering from abdomen tumor were inv estigated.The results showed that the labeling rate of 131I was 80% and th e specific activity of 131I－VIP was 36TBq/mmol. The radiochemical purity of 131I－VIP was over 98%, and it decreased to 95% after six hours' storage a t 4℃. It was proved that the 131I－VIP eluate had no bacteria, no pyrogen and no poison. The injected 131I－VIP was distributed into the lungs immediately and was eliminated through kidneys. The primary tumor could be visualized about half an hour to 3 hours after injection. This study demonstrates that 131I－VIP is suitable for in vivo imaging and may be used as an effective tracer to identify the tumor site in patients with VIP receptor positive carcinoma.

关 键 词：^131I-VIP 受体 胃肠道肿瘤 放射性核素显像 

分 类 号：R735[医药卫生—肿瘤] R817[医药卫生—临床医学]